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Abstract
Hyperprolactinaemia, a common side effect of some antipsychotic drugs, is also present in drug-naı¨ve psychotic patients
and subjects at risk for psychosis. Recent studies in non-psychiatric populations suggest that increased prolactin may have
negative effects on cognition. The aim of our study was to explore whether high plasma prolactin levels are associated with
poorer cognitive functioning in subjects with early psychoses. We studied 107 participants: 29 healthy subjects and 78
subjects with an early psychosis (55 psychotic disorders with,3 years of illness, 23 high-risk subjects). Cognitive assessment
was performed with the MATRICS Cognitive Consensus Cognitive Battery, and prolactin levels were determined as well as
total cortisol levels in plasma. Psychopathological status was assessed and the use of psychopharmacological treatments
(antipsychotics, antidepressants, benzodiazepines) recorded. Prolactin levels were negatively associated with cognitive
performance in processing speed, in patients with a psychotic disorder and high-risk subjects. In the latter group, increased
prolactin levels were also associated with impaired reasoning and problem solving and poorer general cognition. In a
multiple linear regression analysis conducted in both high-risk and psychotic patients, controlling for potential confounders,
prolactin and benzodiazepines were independently related to poorer cognitive performance in the speed of processing
domain. A mediation analysis showed that both prolactin and benzodiazepine treatment act as mediators of the
relationship between risperidone/paliperidone treatment and speed of processing. These results suggest that increased
prolactin levels are associated with impaired processing speed in early psychosis. If these results are confirmed in future
studies, strategies targeting reduction of prolactin levels may improve cognition in this population.
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Introduction
Hyperprolactinaemia is a common condition in subjects with a
psychotic disorder. As dopamine is the main prolactin inhibiting
factor, hyperprolactinaemia is a common consequence of D2
receptor blockade in the tuberoinfundibular dopaminergic path-
way [1,2] by antipsychotic drugs. However, increased prolactin
levels have also been reported in drug-naı¨ve patients with a first
psychotic episode or at risk mental states [3–5]. The mechanisms
that mediate the increase of prolactin levels in psychotic subjects
not receiving antipsychotic drugs are poorly understood. More-
over, prolactin levels may be increased by stress [6], which may in
turn contribute to the increased prolactin levels in drug-naı¨ve
psychotic populations.
The most studied consequences of hyperprolactinaemia in
psychotic subjects are amenorrhoea, galactorrhoea, sexual impair-
ment and infertility [7,8]. A recent study conducted in non-
psychiatric population suggests that increased prolactin may have
negative effects on cognition [9]. This prospective study examined
the cognitive changes during late pregnancy and the early
postpartum period, and their possible association with fluctuating
hormone levels (estradiol, progesterone, testosterone, prolactin and
cortisol). A total of 55 pregnant women and 21 controls were
studied, with a neuropsychological assessment during the third
trimester of pregnancy and retest during the early postpartum
period. They concluded that very high and very low levels of
cortisol were associated with poorer performance in certain
cognitive domains, but the most novel finding was that they
found a negative linear association between prolactin levels and
executive function scores, suggesting that higher levels of prolactin
are detrimental to executive function abilities. Animal studies also
support a role for prolactin in the modulation of non-spatial
cognitive tasks [10]. In this recent study, the induction of
hyperprolactinaemia in male rats receiving pituitary grafts was
associated with impaired object recognition. Other studies have
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reported an association between low gonadal steroid levels and
poorer cognitive abilities [11,12]. To our knowledge, there are no
studies addressing whether high prolactin levels often found in
psychotic patients can contribute to the cognitive impairment of
patients with a psychotic disorder.
Subjects with schizophrenia show mild to moderate cognitive
impairment, and perform an average of 1.5 to 2 standard
deviations below population norms [13,14]. These cognitive
alterations appear before the onset of the first psychotic episode
[15,16] and are an important determinant of functional outcome
[17]. Early intervention in psychosis is a novel approach to mental
health care that includes treatment of both psychotic disorders at
first years after the onset (defined as a critical period in the first 3 to
5 years after the onset) as well as subjects with prodromal
symptoms who are at risk for psychosis (high-risk, HR). Early
intervention services have been developed to reduce the duration
of untreated psychosis, a variable that has been associated with a
poorer prognosis of the illness and poorer cognitive performance
[18].
Some studies have shown that atypical antipsychotic drugs have
a better cognitive profile than typicals [19–22], but this remains
controversial. Antipsychotic drugs differ in their affinity at
muscarinic receptors, with detrimental effects on cognitive abilities
in those antipsychotics with higher anticholinergic activity [23].
However, whether different antipsychotic medications exert any
benefits on cognitive performance remains questionable [24,25].
Based on the degree of blockade of D2 receptors at this pathway,
the risk of hyperprolactinaemia differs among different antipsy-
chotics, being greater for typical antipsychotics and some atypicals
including risperidone and paliperidone [26,27]. Also, concomitant
Table 1. Clinical and cognitive variables by diagnostic groups.
Healthy subjects (HS)
N=29
High-Risk (HR)
N=23
Psychotic disorder
(PD) N=55 P value{
Age (years) 26.4 (4.3) 22.5 (4.3) 24.5 (5.3) 0.019b
Female gender 14 (48.3) 5 (21.7) 25 (45.5) 0.100
PANSS positive – 9.9 (2.8) 10.3 (3.6) 0.094
PANSS negative – 13.2 (6.2) 14.4 (5.5) 0.870
PANSS general – 28 (7.4) 25.6 (7.4) 0.180
Calgary Depression Scale – 3.8 (0.8) 3.3 (0.4) 0.555
Plasma prolactin (mg/L) 15.5 (6.3) 27.5 (29.0) 44.4 (40.7) ,0.001a
Plasma total cortisol (mg/dL) 17.7 (6.1) 19.8 (1.5) 18.8 (5.5) 0.468
MCCB cognitive domains (T-scores)
Speed of processing 50.8 (9.9) 41.4 (11.4) 34.5 (12.6) ,0.001a,b
Attention and vigilance 44.9 (9.4) 37.0 (10.1) 36.8 (9.5) 0.001a,b
Working memory 44.6 (9.6) 37.0 (8.2) 36.7 (9.1) 0.002a,b
Verbal learning 48.9 (9.8) 43.9 (7.7) 41.9 (7.9) ,0.001a
Visual learning 50.5 (6.2) 44.9 (9.3) 37.3 (12.3) ,0.001a,b
Reasoning and problem solving 49.0 (8.5) 44.5 (10.2) 41.8 (9.7) 0.006a
Social cognition 52.1 (10.6) 47.4 (11.4) 39.5 (11.1) ,0.001a,b
Composite factor (global) 47.6 (8.6) 37.3 (7.5) 32.0 (9.4) ,0.001a,b
Psychopharmacological treatment`
Antipsychotic treatment
None 29 (100) 17 (73.9) 10 (18.2) ,0.001
Risperidone/Paliperidone in monotherapy 0 (0) 3 (13.0) 17 (30.9)
Olanzapine/Quetiapine in monotherapy 0(0) 0 (0) 14 (25.5)
Aripiprazole in monotherapy 0 (0) 2 (8.7) 6 (10.9)
Polytherapy 0 (0) 1 (4.3) 8 (14.5)
Benzodiazepine treatment 0 (0) 3 (13.0) 12 (21.8) 0.370
Biperiden treatment 0 (0) 1 (4.3) 7 (12.7) 0.266
Antidepressant treatment 0 (0) 14 (60.9) 8 (14.5) ,0.001
Substance use
Tobacco (cigarettes/day) 1.8 (4.6) 3.3 (6.1) 9.4 (9.9) ,0.001a,c
Cannabis (joint/day) 0 (0) 0.4 (1.5) 1.9 (4.6) 0.035
Alcohol (standard units/day) 0.1 (0.4) 0 (0) 0.8 (2.4) 0.097
Data are mean (SD) or N (%). Four participants (3 PD, 1 HR) had missing data for prolactin analyses.
Abbreviation: PANSS = Positive and Negative Syndrome Scale; MCCB = MATRICS Consensus Cognitive Battery.
{One-way ANOVA was used to compare continuous data among groups. Chi-square test was used to compare categorical data among groups.
`Psychopharmacologic treatment was compared between PD and HR groups (HS were excluded in the comparison).
Significant ANOVA post-hoc analyses (with Bonferroni adjustment) are highlighted: a HS vs PD, bHS vs HR, cPD vs HR.
doi:10.1371/journal.pone.0089428.t001
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treatment with anticholinergics or benzodiazepines can also have
deleterious effects on cognition [28–30].
The main aim of our study was to explore whether prolactin
levels are associated with poorer cognitive functioning in subjects
with early psychoses, including both first episode of psychosis and
high-risk subjects. We hypothesized that increased prolactin is
associated with poorer cognitive performance in subjects with
early psychoses. We also aimed to determine whether prolactin
may mediate the relationship between antipsychotic drugs and
cognition while adjusting for other potential contributors (e.g.
adjunctive treatment with benzodiazepines or anticholinergic
drugs).
Materials and Methods
Ethics Statement
All procedures are in accordance with the Declaration of
Helsinki. Ethical approval was obtained from the Committee for
Ethical Clinical Investigation of the Hospital Sant Joan de Reus. The
capacity of the patients to provide informed consent was evaluated
and confirmed by a psychiatrist. After complete description of the
study to the subjects, written informed consent was obtained from
all participants (or their guardians if the patients had a
compromised capacity). All potential participants who declined
to participate or otherwise did not participate were not disadvan-
taged in any way by not participating in the study.
Participants
We studied 78 outpatients with an early psychosis, aged
between 18 and 35 years old, attending the Early Psychosis
Program from Reus (HPU Institut Pere Mata, Spain). We
included a control group of 29 healthy subjects (HS) that were
recruited among patients’ friends and non-genetic relatives, and
screened to rule out past or current history of psychiatric disorder.
Early psychosis patients were divided into two different clinical
populations: 1) High risk for psychosis (HR, subjects with
prodromal psychotic symptoms fulfilling set criteria for At Risk
Mental State [31], N=23); 2) Psychotic Disorder with less than 3
years from the onset of the illness (PD, N=55). DSM-IV diagnoses
for the PD group were: schizophreniform disorder (N= 11),
schizophrenia (N= 10), schizoaffective disorder (N= 3), psychotic
disorder not otherwise specified (N= 31). Exclusion criteria were:
pregnancy, mental retardation, severe head injury or neurological
disease, active glucocorticoid treatment, language difficulties,
visual impairment and alcohol, cocaine or heroin dependence.
Characteristics of Patients
All subjects were assessed with the Schedules for Clinical
Assessment in Neuropsychiatry [32]. OPCRIT checklist v.4.0.
(available at http://sgdp.iop.kcl.ac.uk/opcrit/) was used to gen-
erate DSM-IV diagnoses for psychotic disorders. HR subjects were
also assessed with the Comprehensive Assessment of At Risk
Figure 1. Scatter plot of the relationship between prolactin levels and speed of processing T-scores between diagnostic groups
(psychotic disorder vs high-risk).
doi:10.1371/journal.pone.0089428.g001
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Mental States, to ensure that subjects met criteria for any of the
three HR groups defined by At Risk Mental State criteria [31].
Socio-demographic and clinical variables related to psychosis
(age at onset, antipsychotic treatment, substance use) were assessed
by semistructured interview. Tobacco, cannabis and alcohol
consumption were registered in cigarettes/day, joints/day and
standard units/day respectively. Positive and Negative Symptom
Scale [33] was administered to explore positive, negative and
overall psychotic symptoms. Calgary Depression Scale [34] was
administered to explore depressive symptoms. These scales were
administered the same day of the cognitive assessment.
Psychopharmacological treatment at neuropsychological assess-
ment was registered. Of all 78 patients, 27 (34.6%) were not taking
antipsychotics, 42 (53.8%) were on antipsychotic monotherapy
(risperidone [n= 20], paliperidone [n= 5], olanzapine [n = 13],
quetiapine [n = 1], aripiprazole [n= 8]) and 9 (11.5%) were on
polytherapy.
Each antipsychotic dose was transformed into chlorpromazine
equivalents in mg/day [35]. We recoded chlorpromazine equiv-
alent doses into three different variables taking into account the
mechanism of action of each antipsychotic and its effects on
prolactin and anticholinergic activity: 1) risperidone/paliperidone
(prolactin elevating without anticholinergic activity), 2) olanza-
pine/quetiapine/clozapine (prolactin sparing with anticholinergic
activity) and 3) aripiprazole (prolactin sparing without anticholin-
ergic activity). Benzodiazepine treatment was registered in
diazepam equivalent doses. Biperiden dose was registered in
mg/day. Antidepressant treatment was registered as fluoxetine
equivalents in mg/day.
Cognitive Assessment
The MATRICS Consensus Cognitive Battery (MCCB) was
administered to explore neuropsychological functioning [36]. This
cognitive battery has demonstrated practicality of administration,
high test-retest reliability, small practice effects, small ceiling effects
and relationship to functional outcome. The MCCB contains 10
tests to measure cognitive performance in 7 cognitive domains:
speed processing, attention/vigilance, working memory, verbal
learning, visual learning, reasoning and problem solving, and
social cognition (Table S1). A composite Score is obtained, which
combines the individual scores of the 10 tests and scores them on a
normative scale to derive a T-score, where the mean is 50 and a
standard deviation is 10 for the composite. Normative data for the
MCCB has been obtained in Spain [37], suggesting that significant
age, gender, and education effects are comparable to those effects
described for the original standardized English version in the U.S.
All neuropsychological assessments were performed in the
morning, with starting times between 9 h and 12 h. Cognitive
testing in PD was assessed when they were clinically stable.
Hormonal Measures
A fasting blood sample was obtained in the morning between
8:30 h and 9:30 h in resting conditions, to determine unstimulated
plasma prolactin and total cortisol levels. Participants were told to
avoid stressful activities (sports, physical exercise) or breast
stimulation in the 12 hours prior to blood sampling. Prolactin
and cortisol concentrations were measured using the Maglumi
2000 Analyzer chemiluminescence immunoassay system (SNIBE
Co, Ltd, Guandong, China). The sensitivity of the prolactin assay
was 1.77 mg/L.
Statistical Analysis
The SPSS version 19.0 software (SPSS Inc., Chicago, Illinois,
USA) was used to carry out the statistical analyses. As prolactin
levels, PANSS and CDS scores were skewed, we log transformed
(ln) these variables to reduce skewness. Chi-square tests and one-
way ANOVA were used to compare categorical and continuous
Table 2. Correlation between prolactin levels and MCCB cognitive domains (T-scores) and psychopharmacological treatments.
Healthy subjects (N=29)
Prolactin* High-Risk (N=23) Prolactin*
Psychotic disorder (N=55)
Prolactin*
r P r P r P
Speed of processing 20.023 0.906 20.498 0.018 20.286 0.040
Attention and vigilance 0.040 0.838 20.128 0.569 20.070 0.625
Working memory 20.043 0.826 20.150 0.504 0.119 0.400
Verbal learning 20.302 0.111 20.236 0.290 20.037 0.795
Visual learning 20.159 0.411 20.303 0.181 0.016 0.910
Reasoning and problem solving 0.083 0.670 20.449 0.036 0.001 0.992
Social cognition 0.191 0.321 0.212 0.370 0.119 0.420
Composite (global) 20.042 0.830 20.458 0.049 0.137 0.369
Risperidone/Paliperidone dose{ 0.372 0.088 0.479 ,0.001
Olanzapine/Clozapine/Quetiapine dose{ 0.074 0.744 0.131 0.355
Aripiprazole dose{ 20.263 0.237 20.203 0.149
Benzodiazepine dose` 20.049 0.828 0.270 0.053
Biperiden dose (mg/day) 0.389 0.074 0.122 0.389
Antidepressant dose1 0.135 0.549 20.030 0.831
Stratified analysis by diagnostic group.
* Log transformed (ln) values of prolactin.
{In equivalents of chlorpromazine (mg/day).
`In equivalents of diazepam (mg/day).
1In equivalents of fluoxetine (mg/day).
doi:10.1371/journal.pone.0089428.t002
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data between groups. Post-hoc ANOVA analyses were adjusted
with a Bonferroni correction. Spearman correlation was used to
explore the association between continuous or ordinal variables.
Significance was set at p,0.05 (two-tailed). For all statistical
analyses we used MCCB T-scores corrected for age, gender and
education level.
We first divided the sample by diagnostic group (HS, PD and
HR). A stratified analysis by diagnostic group was conducted to
explore the association between prolactin levels and cognitive
measures in each subgroup of participants.
A multiple linear regression analysis was performed in all
patients (including both PD and HR subjects) to explore the
relationship between plasma prolactin levels (main independent
variable) and MCCB cognitive domains (dependent variable) while
controlling for covariables such as other psychopharmacological
treatments, psychopathological status, smoking and other sub-
stance use (cannabis and alcohol) and cortisol.
Furthermore, those MCCB domains that showed a significant
association with prolactin in the multivariate analyses were also
tested with a mediation analysis to explore whether the effect of
antipsychotic treatment on cognition could be mediated by
prolactin levels and benzodiazepine treatment. We conducted a
mediation analysis according to Baron and Kenny [38] and used
bootstrapping to test the indirect effect of mediation [39]. A
description of mediation analysis is shown in Box S1.
We used a SPSS macro [40] that allows the inclusion of multiple
mediators and covariates. In this mediation analysis, we decided to
include risperidone/paliperidone dose as the main independent
variable because its elevating effect on prolactin levels. MCCB
cognitive T-score (e.g. Speed of Processing) was used as the
dependent variable. Two potential mediators were considered:
prolactin and benzodiazepine treatment. We included as covar-
iates other antipsychotic drugs, biperiden and antidepressant
treatments. Significance of the indirect effects in this model was
tested by bootstrapping.
R and ggplot2 package (http://www.r-project.org/) were used
to draw scatterplot figures exploring the association between
prolactin and MCCB cognitive domains.
Results
Univariate Analyses
Clinical characteristics of the sample by diagnostic group are
described in Table 1. As expected, we found that HS performed
significantly better than PD in all cognitive domains, and better
than HR in most domains (Table 1). There were no significant
differences in psychopathological scales between PD and HR. PD
Figure 2. Results of the mediation analysis exploring the relationship between risperidone/paliperidone dose and processing
speed in subjects with early psychoses. Log transformed (ln) levels of prolactin were used in the mediation analysis. The mediated effect (b) was
adjusted for the following covariates: olanzapine/clozapine/quetiapine dose (b= 0.002, SE = 0.008, P = 0.848), aripiprazole dose (b=20.016,
SE = 0.011, P = 0.151), biperiden dose (b=20.567, SE = 1.486, P = 0.704) and antidepressant dose (b= 0.048, SE = 0.101, P = 0.638). Abbreviations:
b= unstandardized regression coefficient; SE = standard error.
doi:10.1371/journal.pone.0089428.g002
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subjects were more frequently treated with antipsychotics, when
compared to HR. However, the latter group was more frequently
treated with antidepressants.
In the stratified analysis by diagnostic group, prolactin levels
were significantly associated with processing speed in both PD and
HR subjects (Table 2). In HR subjects, prolactin levels were also
related with poorer cognitive performance in reasoning and
problem solving, and global cognition. A scatter plot by diagnostic
group (PD vs HR) is shown in Figure 1. We also performed
another analysis including both HR and PD together (Table S2).
In this analysis, prolactin was positively associated with risperi-
done/paliperidone and benzodiazepine doses and negatively
associated with speed of processing.
Multivariate Analyses
In the multivariate analysis conducted in both HR and PD
groups, the significant negative association between prolactin and
speed of processing was maintained after adjusting for psycho-
pharmacological treatments, smoking and substance use (cannabis
and alcohol consumption), severity of psychotic symptoms and
cortisol levels (Table 3). As shown in this table, both prolactin and
risperidone/paliperidone treatment were related to a poorer
processing speed (Model 2). However, when other drugs were
included in the equation (Model 3), impaired processing speed was
associated with benzodiazepine treatment but not antipsychotic
doses. Other MCCB cognitive domains were not associated with
prolactin levels in the multiple linear regression analyses (Table
S3).
In the mediation analysis, we tested two potential mediators
(prolactin and benzodiazepine treatment) in the relationship
between risperidone/paliperidone doses and processing speed
(Figure 2). In the unadjusted model (a), risperidone/paliperidone
treatment was negatively associated with speed of processing. This
effect was fully mediated by both prolactin and benzodiazepine
treatment (b), as the relationship between antipsychotic treatment
and speed of processing lost its significance when these two
mediators were included in the equation. In this mediated analysis,
other antipsychotics, antidepressants and biperiden were included
as covariates, thus the results are adjusted for these psychophar-
macological drugs. As a multiple mediation model is analogous to
conducting a regression analysis with several predictors testing the
total indirect effect of the independent variable (risperidone/
paliperidone treatment) on the dependent variable (speed of
processing), both prolactin and benzodiazepines are independently
associated with speed of processing. The indirect effects of both
variables account for all the observed relationship between
risperidone/paliperidone treatment and speed of processing.
Bootstrap results for indirect effects were significant for both
prolactin (95% CI: 20.165 to –0.001) and benzodiazepine
treatment (95% CI: 20.167 to –0.002).
Discussion
Our study suggests that increased prolactin levels are associated
with impaired processing speed independent of antipsychotic
drugs in subjects with early psychosis. In HR subjects only,
increased prolactin was also associated with impaired reasoning
and problem solving and poorer general cognition. The results of
the mediation analysis also showed that the effect of risperidone/
paliperidone treatment on speed of processing is mediated by both
prolactin levels and benzodiazepine treatment. To our knowledge,
this is the first study to highlight prolactin as an important
contributor to cognitive impairment in subjects with psychosis.
Regarding speed of processing, our results are consistent with
previous studies reporting that processing speed is the first
cognitive domain to be affected in psychotic disorders at early
stages [41] and in at risk mental states subjects [42]. This cognitive
domain, that may be considered a core feature of schizophrenia
neurocognitive impairment, is thought to mediate the relationship
between cognitive symptoms and functional outcome in schizo-
phrenia [43]. In contrast to other cognitive domains, speed of
processing is considered a ‘‘system based’’ domain, reflecting a
process of integration and coordination between distributed brain
networks [44]. This is in line with the disconnection hypothesis of
schizophrenia, which asserts that impaired communication within
the brains of schizophrenia patients occurs when there is focal
disruption that adversely affects the entire network. Speed of
processing deficits may point to aberrant functional connectivity
within and between whole brain neural systems, rather than
indexing impairment in discrete neural networks [45].
Although antipsychotic drugs are a common cause of hyper-
prolactinaemia, other studies in drug-naı¨ve patients have also
shown increased prolactin levels in PD and HR subjects [3–5].
Interestingly, in our study the relationship between prolactin and
processing speed was also found in HR subjects, most of whom
were not receiving antipsychotic treatment. Moreover, in the
multivariate analyses, the association between prolactin levels and
impaired processing speed remained significant after adjusting for
psychopharmacological treatments. Prolactin is a hormone that
may be raised in stressful situations. We accounted for this by
controlling for cortisol levels in the multivariate analysis, and the
effect of prolactin on cognition was independent of hypothalamic-
pituitary-adrenal axis activity.
Antipsychotic-induced hyperprolactinaemia, which is caused by
tuberoinfundibular blockade of D2 receptors, may be reflecting
the blockade of D2 receptors in other dopaminergic pathways
including the striatum, which causes extrapyramidal symptoms, or
the mesocortical pathway, that may be related to worsening in
cognitive and negative symptoms. The mediated analysis suggests
that the negative effect of risperidone/paliperidone on processing
speed is mediated by both prolactin and benzodiazepines. This
could be explained by the prolactin-elevating profile of these
antipsychotics as well as the induction of extrapyramidal
symptoms (e.g. akathysia) that are often treated with benzodiaz-
epines.
Our study suggests that prolactin may be considered as a
biomarker that is associated with impaired processing speed in
subjects with early psychoses. This finding may have important
clinical implications. Further studies are needed to explore
whether a reduction in prolactin levels by optimizing psychophar-
macological treatment leads to an improvement in processing
speed.
The main limitation of our study is the cross-sectional design
that does not allow us to infer causality. Further prospective studies
may overcome this limitation by repeatedly assessing prolactin
levels and cognitive performance over time to explore whether
persistent hyperprolactinaemia is a risk factor for cognitive decline
in subjects with psychoses. We did not control for other hormones
that may affect cognition such as sex steroids. Hyperprolactinae-
mia inhibits the hypothalamic-pituitary-gonadal axis [7], and
hypogonadism secondary to hyperprolactinaemia may contribute
to the negative effects of prolactin on cognition. However, in order
to control for these variables, larger samples are required because
a sex-stratified analysis is necessary (controlling for estradiol in
women and testosterone in men).
We designed a pragmatic study with consecutive sampling in an
Early Intervention Service. For this reason, the sample of our
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study included both HR subjects and psychotic disorders at early
stages, and patients were treated with different antipsychotics that
were chosen by clinicians based on the clinical routine practice.
HR subjects and PD patients exhibited similar PANSS scores. As
our Early Intervention Service is an outpatient service, some
patients who have been previously admitted to the referral Acute
Psychiatric Unit are stabilized before attending our service.
Moreover, patients need to be informed of the research project
and must sign the informed consent; thus in most cases, PD
patients are clinically stable at recruitment. As most PD patients
have been treated before entering the study, the PANSS scores
reflect the psychopathological state at the neuropsychological
assessment (not at the acute phase of the illness). These
characteristics could explain why both groups (HR and PD)
exhibited similar PANSS scores. Although HR group shares some
characteristics with PD group at early stages such as cognitive
impairment, only 30% develop psychosis at one year [46]. From
our cross-sectional design we do not know whether prolactin could
be a biomarker related to the risk of transition to psychosis. Future
prospective studies are needed to clarify this question. Finally, the
sample of our study was composed by outpatients, and none of
whom were receiving first-generation antipsychotics. Thus, our
results may not be generalizable to other populations including
inpatients, psychotic patients with a longer duration of illness or
patients taking typical antipsychotics. In fact, a recent study
conducted in patients with chronic schizophrenia showed that
switching to aripiprazole led to a decrease in prolactin levels but
was not associated with cognitive improvement [47]. Our results
should be replicated in other samples to draw definite conclusions.
However, several strengths of our study need to be highlighted:
1) our study is the first to describe the potential role of prolactin on
cognition in subjects with psychoses, 2) we have used a
standardized neurocognitive battery (MCCB) to assess cognition,
3) the sample included subjects with a short duration of the illness,
and 4) we controlled for potential confounders such as concom-
itant antipsychotic medication (chlorpromazine equivalents) by
differentiating antipsychotics depending upon their mechanism of
action, as well as controlling for benzodiazepines that have been
suggested as moderating factors of processing speed [48], and 5)
we also controlled for smoking status, which has been describe to
modify prolactin levels [49] and to interfere with cognition in early
psychosis patients [50].
Conclusions
In summary, our study suggests that increased prolactin levels
are associated with impaired processing speed in early psychosis
and that also mediate the negative effects of prolactin elevating
antipsychotics on processing speed. If these results are replicated in
further studies, hyperprolactinaemia may be considered as a
potential contributor to cognitive deterioration in psychotic
subjects and strategies targeting reduction of prolactin levels may
improve cognition in this population.
Supporting Information
Table S1 MATRICS Consensus Cognitive Battery tests and
cognitive domains.
(DOC)
Table S2 Correlations between prolactin levels, psychopharma-
cological treatment, psychopathological status and MCCB cogni-
tive domains in subjects with early psychosis.
(DOC)
Table S3 Multiple regression analyses exploring the relationship
between prolactin levels in plasma and MCCB Cognitive domains
in subjects with early psychosis.
(DOC)
Box S1 Explanation of the mediation analysis.
(DOC)
Acknowledgments
We thank Antoni Trill for analyzing plasma samples.
Author Contributions
Conceived and designed the experiments: JL AGZ RMR SML. Performed
the experiments: IM MC JF LO RM. Analyzed the data: JL IM.
Contributed reagents/materials/analysis tools: RMR EV. Wrote the
paper: IM RMR EV JL.
References
1. Fitzgerald P, Dinan TG (2008) Prolactin and dopamine: What is the connection?
A review article. J Psychopharmacol 22: 12–19.
2. Inder WJ, Castle D (2011) Antipsychotic-induced hyperprolactinaemia.
Aust N Z J Psychiatry 45: 830–837.
3. Aston J, Rechsteiner E, Bull N, Borgwardt S, Gschwandtner U, et al (2010)
Hyperprolactinaemia in early psychosis-not only due to antipsychotics. Prog
Neuropsychopharmacol Biol Psychiatry 34: 1342–1344.
4. Garcia-Rizo C, Fernandez-Egea E, Oliveira C, Justicia A, Parellada E, et al
(2012) Prolactin concentrations in newly diagnosed, antipsychotic-naive patients
with nonaffective psychosis. Schizophr Res 134: 16–19.
5. Riecher-Rossler A, Rybakowski JK, Pflueger MO, Beyrau R, Kahn RS, et al
(2013) Hyperprolactinemia in antipsychotic-naive patients with first-episode
psychosis. Psychol Med : 1–12.
6. Lennartsson AK, Jonsdottir IH (2011) Prolactin in response to acute
psychosocial stress in healthy men and women. Psychoneuroendocrinology 36:
1530–1539.
7. Halbreich U, Kahn LS (2003) Hyperprolactinemia and schizophrenia:
Mechanisms and clinical aspects. J Psychiatr Pract 9: 344–353.
8. Johnsen E, Kroken R, Loberg EM, Kjelby E, Jorgensen HA (2011) Sexual
dysfunction and hyperprolactinemia in male psychotic inpatients: A cross-
sectional study. Adv Urol 2011: 686924.
9. Henry JF, Sherwin BB (2012) Hormones and cognitive functioning during late
pregnancy and postpartum: A longitudinal study. Behav Neurosci 126: 73–85.
10. Torner L, Tinajero E, Lajud N, Quintanar-Stephano A, Olvera-Cortes E (2013)
Hyperprolactinemia impairs object recognition without altering spatial learning
in male rats. Behav Brain Res 252: 32–39.
11. Sherwin BB (2012) Estrogen and cognitive functioning in women: Lessons we
have learned. Behav Neurosci 126: 123–127.
12. Wolf OT, Kirschbaum C (2002) Endogenous estradiol and testosterone levels
are associated with cognitive performance in older women and men. Horm
Behav 41: 259–266.
13. Bilder RM, Goldman RS, Robinson D, Reiter G, Bell L, et al (2000)
Neuropsychology of first-episode schizophrenia: Initial characterization and
clinical correlates. Am J Psychiatry 157: 549–559.
14. Heinrichs RW, Zakzanis KK (1998) Neurocognitive deficit in schizophrenia: A
quantitative review of the evidence. Neuropsychology 12: 426–445.
15. Davidson M, Reichenberg A, Rabinowitz J, Weiser M, Kaplan Z, et al (1999)
Behavioral and intellectual markers for schizophrenia in apparently healthy male
adolescents. Am J Psychiatry 156: 1328–1335.
16. Reichenberg A, Weiser M, Rapp MA, Rabinowitz J, Caspi A, et al (2005)
Elaboration on premorbid intellectual performance in schizophrenia: Premorbid
intellectual decline and risk for schizophrenia. Arch Gen Psychiatry 62: 1297–
1304.
17. Green MF (1996) What are the functional consequences of neurocognitive
deficits in schizophrenia? Am J Psychiatry 153: 321–330.
18. Cuesta MJ, Garcia de Jalon E, Campos MS, Ibanez B, Sanchez-Torres AM, et
al (2012) Duration of untreated negative and positive symptoms of psychosis and
cognitive impairment in first episode psychosis. Schizophr Res 141: 222–227.
19. Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, et al (2002)
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in
patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry
159: 1018–1028.
20. Purdon SE, Malla A, Labelle A, Lit W (2001) Neuropsychological change in
patients with schizophrenia after treatment with quetiapine or haloperidol.
J Psychiatry Neurosci 26: 137–149.
Prolactin and Processing Speed in Early Psychosis
PLOS ONE | www.plosone.org 8 February 2014 | Volume 9 | Issue 2 | e89428
21. Harvey PD. (2003) Ziprasidone and cognition: The evolving story. J Clin
Psychiatry 64 Suppl 19: 33–39.
22. Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, et al (2004)
Comparative effect of atypical and conventional antipsychotic drugs on
neurocognition in first-episode psychosis: A randomized, double-blind trial of
olanzapine versus low doses of haloperidol. Am J Psychiatry 161: 985–995.
23. Chew ML, Mulsant BH, Pollock BG, Lehman ME, Greenspan A, et al (2006) A
model of anticholinergic activity of atypical antipsychotic medications.
Schizophr Res 88: 63–72.
24. Mishara AL, Goldberg TE (2004) A meta-analysis and critical review of the
effects of conventional neuroleptic treatment on cognition in schizophrenia:
Opening a closed book. Biol Psychiatry 55: 1013–1022.
25. Woodward ND, Purdon SE, Meltzer HY, Zald DH (2007) A meta-analysis of
cognitive change with haloperidol in clinical trials of atypical antipsychotics:
Dose effects and comparison to practice effects. Schizophr Res 89: 211–224.
26. Maguire GA (2002) Prolactin elevation with antipsychotic medications:
Mechanisms of action and clinical consequences. J Clin Psychiatry 63 Suppl
4: 56–62.
27. Cookson J, Hodgson R, Wildgust HJ (2012) Prolactin, hyperprolactinaemia and
antipsychotic treatment: A review and lessons for treatment of early psychosis.
J Psychopharmacol 26: 42–51.
28. Harvey PD, Keefe RS (2001) Studies of cognitive change in patients with
schizophrenia following novel antipsychotic treatment. Am J Psychiatry 158:
176–184.
29. Keefe RS, Silva SG, Perkins DO, Lieberman JA (1999) The effects of atypical
antipsychotic drugs on neurocognitive impairment in schizophrenia: A review
and meta-analysis. Schizophr Bull 25: 201–222.
30. Carpenter WT, Gold JM (2002) Another view of therapy for cognition in
schizophrenia. Biol Psychiatry 51: 969–971.
31. Yung AR, Phillips LJ, McGorry PD, McFarlane CA, Francey S, et al (1998)
Prediction of psychosis. A step towards indicated prevention of schizophrenia.
Br J Psychiatry Suppl 172: 14–20.
32. Wing JK, Babor T, Brugha T, Burke J, Cooper JE, et al (1990) SCAN. schedules
for clinical assessment in neuropsychiatry. Arch Gen Psychiatry 47: 589–593.
33. Kay SR, Fiszbein A, Vital-Herne M, Fuentes LS (1990) The positive and
negative syndrome scale–spanish adaptation. J Nerv Ment Dis 178: 510–517.
34. Addington D, Addington J, Schissel B (1990) A depression rating scale for
schizophrenics. Schizophr Res 3: 247–251.
35. Gardner DM, Murphy AL, O’Donnell H, Centorrino F, Baldessarini RJ (2010)
International consensus study of antipsychotic dosing. Am J Psychiatry 167:
686–693.
36. Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, et al (2008) The
MATRICS consensus cognitive battery, part 1: Test selection, reliability, and
validity. Am J Psychiatry 165: 203–213.
37. Rodriguez-Jimenez R, Bagney A, Garcia-Navarro C, Aparicio AI, Lopez-Anton
R, et al (2012) The MATRICS consensus cognitive battery (MCCB): Co-
norming and standardization in spain. Schizophr Res 134: 279–284.
38. Baron RM, Kenny DA (1986) The moderator-mediator variable distinction in
social psychological research: Conceptual, strategic, and statistical consider-
ations. J Pers Soc Psychol 51: 1173–1182.
39. Shrout PE, Bolger N (2002) Mediation in experimental and nonexperimental
studies: New procedures and recommendations. Psychol Methods 7: 422–445.
40. Preacher KJ, Hayes AF (2008) Asymptotic and resampling strategies for
assessing and comparing indirect effects in multiple mediator models. Behav Res
Methods 40: 879–891.
41. Dickinson D, Ramsey ME, Gold JM (2007) Overlooking the obvious: A meta-
analytic comparison of digit symbol coding tasks and other cognitive measures in
schizophrenia. Arch Gen Psychiatry 64: 532–542.
42. Riecher-Rossler A, Pflueger MO, Aston J, Borgwardt SJ, Brewer WJ, et al (2009)
Efficacy of using cognitive status in predicting psychosis: A 7-year follow-up. Biol
Psychiatry 66: 1023–1030.
43. Ojeda N, Pena J, Sanchez P, Elizagarate E, Ezcurra J (2008) Processing speed
mediates the relationship between verbal memory, verbal fluency, and functional
outcome in chronic schizophrenia. Schizophr Res 101: 225–233.
44. Dickinson D (2008) Digit symbol coding and general cognitive ability in
schizophrenia: Worth another look? Br J Psychiatry 193: 354–356.
45. Kelleher I, Murtagh A, Clarke MC, Murphy J, Rawdon C, et al (2012)
Neurocognitive performance of a community-based sample of young people at
putative ultra high risk for psychosis: Support for the processing speed
hypothesis. Cogn Neuropsychiatry.
46. Fusar-Poli P, Bonoldi I, Yung AR, Borgwardt S, Kempton MJ, et al (2012)
Predicting psychosis: Meta-analysis of transition outcomes in individuals at high
clinical risk. Arch Gen Psychiatry 69: 220–229.
47. Lee BJ, Lee SJ, Kim MK, Lee JG, Park SW, et al (2013) Effect of aripiprazole on
cognitive function and hyperprolactinemia in patients with schizophrenia treated
with risperidone. Clin Psychopharmacol Neurosci 11: 60–66.
48. Stewart SA (2005) The effects of benzodiazepines on cognition. J Clin Psychiatry
66 Suppl 2: 9–13.
49. Zhang X, Bu R, Sha W, Wang X, Liu J, et al (2013) Serum prolactin and
smoking status in chronic antipsychotic-treated male patients with schizophre-
nia. Psychiatry Res 209: 239–241.
50. Segarra R, Zabala A, Eguiluz JI, Ojeda N, Elizagarate E, et al (2011) Cognitive
performance and smoking in first-episode psychosis: The self-medication
hypothesis. Eur Arch Psychiatry Clin Neurosci 261: 241–250.
Prolactin and Processing Speed in Early Psychosis
PLOS ONE | www.plosone.org 9 February 2014 | Volume 9 | Issue 2 | e89428
